News

In the first model, ADX71943 reversed complete Freund adjuvant (CFA)- induced reductions in withdrawal thresholds in a dose-related manner, with a minimum effective oral dose of 10mg/kg. In

The company has partnered with Fujirebio Diagnostics in the development of the assay. The Architect HE4 assay has been approved for use in Europe, as well as in

As per terms of the agreement, Safecor Health is expected to provide Premier members a flexible and comprehensive menu of unit-dose and bar-coded repackaging services geared toward each

The new patent is based on the research by Alnylam scientists on systemic delivery of RNAi therapeutics as documented in Soutschek et al (Nature 432, 173-178 (11 November

The technology is based on a naturally occurring polysialic acid, which extends active life of a protein. PSA is biodegradable, non-immunogenic and non-toxic and is, therefore, expected to

As per the new agreement, Teva has extended its marketing and distribution rights to include the Nordic and Baltic regions, previously held by Active Biotech. Active Biotech is

SUN Y7017 is an N-methyl-D-aspartate (NMDA) receptor antagonist developed by Merz Pharmaceuticals. This drug was approved for use in the treatment of AD by the EMEA in 2002,

The Phase 2-3, multi-center, randomised, double-blind, placebo-controlled and international study is expected to evaluate the efficacy and safety of inhaled, human AAT in alpha-1 deficient patients with emphysema.

Novavax said that the decision was taken due to the companies’ inability to agree on acceptable terms of the proposed collaboration and to obtain the necessary funding commitments